

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein will not be registered under the Securities Act or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in transactions not subject to, the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. The Company does not intend to make any public offering of securities in the United States.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

**PROPOSED SPIN-OFF AND SEPARATE LISTING OF
JBM (HEALTHCARE) LIMITED
ON THE MAIN BOARD OF
THE STOCK EXCHANGE OF HONG KONG LIMITED**

POST HEARING INFORMATION PACK

References are made to the Company's announcements (the "Announcements") dated 23 September 2020 and 15 January 2021 relating to the Proposed Spin-off. Unless the context requires otherwise, terms used herein shall have the same meanings as defined or used in the Announcements.

POST HEARING INFORMATION PACK

JBM has submitted the post hearing information pack (the “**PHIP**”) in relation to the Proposed Spin-off to the Stock Exchange for publication on the Stock Exchange’s website. The PHIP is available for viewing and downloading from the Stock Exchange’s website (www.hkexnews.hk). The PHIP contains, among other things, certain business and financial information relating to the Spin-off Group. Shareholders should note that the PHIP is in draft form and the information contained in the PHIP is incomplete and is subject to change which can be material. Shareholders are advised to refer to the Stock Exchange’s website (www.hkexnews.hk) from time to time for the updated PHIP (if any) which is expected to be published by JBM as and when appropriate. The Company does not have any obligation or liability whatsoever in relation to the PHIP and any updated PHIP (if any).

GENERAL

As the Proposed Spin-off is conditional upon, among other things, the approval of the Listing Committee, the Public Offer becoming unconditional in all respects, the final decision of the Board and the board of JBM, market conditions and other considerations, the Proposed Spin-off and the Public Offer may or may not materialise and the Distribution may or may not be made. Shareholders and other investors are reminded to exercise caution when dealing in the securities of the Company. Persons who are in doubt about their position or any action to be taken are recommended to consult their own professional advisers.

The Company will make further announcement(s) in relation to the Proposed Spin-off as and when appropriate.

By order of the Board
Jacobson Pharma Corporation Limited
YIM Chun Leung
Executive Director and Company Secretary

Hong Kong, 21 January 2021

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung (also as Company Secretary) and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.